Measurable weight loss often starts within 2 to 4 weeks, while more significant results typically become noticeable after 8 to 12 weeks of consistent treatment
Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72
As GLP-1 therapy progresses and weight loss occurs, your provider may need to reduce or discontinue some antihypertensive medications to prevent symptomatic low blood pressure, but this decision requires medical supervision and regular blood pressure monitoring
Recent, as yet fragmentary evidence suggests that intervention with GLP1-RA, e.g., liraglutide, may reduce body weight and improve hyperandrogenism and menstrual irregularities in women with obesity and PCOS 28,29,30,31,32
The cardiovascular benefits of specific GLP-1 receptor agonists extend beyond modest blood pressure reductions
During the consultation, the provider reviews medical history, current medications, weight-related health concerns, and safety factors before deciding whether tirzepatide-based treatment may be clinically appropriate
